$FTH

$19.11 +$2.28 (13.55%) Close

$FTH Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Ownership

13F as of Q2 2026 · 25.8M shares outstanding

Who owns FTH?

By type of holder

Institutions 54.5% Insiders 45.5% Everyone else 0.0%

Concentration Top 10 holders own 143.0%

Parikh Anand Kiran 60.1% · Peyer James 40.2%

Institutional ownership

54.5%

+46.1 pts vs last qtr

Institutional holders

+15 vs last qtr

Net shares bought

+11.9M

by institutions in Q2 2026

New / sold out

22 / 7

positions opened vs closed

How is ownership changing?

Institutions, last 8 quarters

Biggest buyers in Q2 2026

Montanova Capital, LLC +2.0M
Avoro Capital Advisors LLC NEW +1.4M

Biggest sellers in Q2 2026

Millennium Management LLC SOLD OUT −146.6K
Stempoint Capital LP SOLD OUT −132.9K

Who is planning to sell?

Notices of proposed sale, last 12 months

$5.35M

7 notices from 4 people

Shares covered

188.5K

0.73% of the company

Arranged in advance

of the value is under a 10b5-1 plan

Under a 10b5-1 plan No plan

Largest proposed sellers

Cambrian BioPharma Inc 10% stockholder $5.19M
Celebi John Former officer $116K

Every notice on Red Flags →

A Form 144 is notice of a planned sale, not the sale itself. What insiders actually sold is on Insider Transactions.

Is your stake being diluted?

Diluted share count, FY2021–FY2025

−9.0%

−2.33% a year

Each share's claim on the business

+9.9%

grew without buying or selling a share

Spent on buybacks vs paid in stock

$10.4M vs $20.3M

over 5 fiscal years

Diluted shares, split-adjusted

Buybacks Stock-based comp

How patient are the owners?

Institutional shares by how long they've been held

5+ years0% 3–5 years0% 1–3 years0% Under 1 year100%

Quarterly turnover

298.7%

of institutional shares changed hands

Top 10 managers, median time held

1 quarter

Super Investors

Investment managers reporting FTH on Form 13F

Holder	Shares	% of company	Change vs last qtr	Held since	% of their book
MC Montanova Capital, LLC	2.0M	7.82%	+2.0M (+5747.1%)	Q1 '26	0.9%
Shares held by quarter Peak holding2.0M (Q2'26) Change over 8 quarters+2.0M Share of the company7.820% Montanova Capital, LLC's full portfolio →
AC Avoro Capital Advisors LLC	1.4M	5.59%	NEW	Q2 '26	0.3%
Shares held by quarter Peak holding1.4M (Q2'26) Change over 8 quarters+1.4M Share of the company5.590% Avoro Capital Advisors LLC's full portfolio →

Montanova Capital, LLC

2.0M

% of company

7.82%

Change vs last qtr

+2.0M (+5747.1%)

Held since

Q1 '26

Avoro Capital Advisors LLC

1.4M

% of company

5.59%

Change vs last qtr

NEW

Held since

Q2 '26

28 more super investors behind a free account

See every manager holding Faeth Therapeutics, Inc, how their position has changed, and how long they've held it.

Institutional Funds

Mutual funds and ETFs reporting FTH on Form N-PORT; together they hold 0.8% of the company

Fund	Position value	Shares	% of company	% of the fund	As of
FB Franklin Biotechnology Discovery Fund Franklin Strategic Series	$4.92M	180.7K	0.70%	0.43%	July 31, 2026
VE Vanguard Extended Market Index Fund Vanguard Index Funds	$253K	10.1K	0.04%	0.00%	June 30, 2026

Franklin Biotechnology Discovery Fund

Franklin Strategic Series

Position value

$4.92M

% of company

0.70%

% of the fund

0.43%

As of

July 31, 2026

Vanguard Extended Market Index Fund

Vanguard Index Funds

Position value

$253K

% of company

0.04%

% of the fund

0.00%

As of

June 30, 2026

9 more funds behind a free account

See every fund holding Faeth Therapeutics, Inc and how much of the fund the position is.

Insiders and 5%+ holders

From Forms 3/4/5 and Schedules 13D/G

Holder	Shares	% of company	Change vs last qtr	8 quarters	Held since	% of their book
PA Parikh Anand Kiran Insider	15.5M	60.12%	—	—	—	—
Insider holdings come from Form 3/4/5 filings, which are not quarterly. Share of the company60.120% Parikh Anand Kiran's insider activity →
PJ Peyer James Insider	10.4M	40.21%	—	—	—	—
Insider holdings come from Form 3/4/5 filings, which are not quarterly. Share of the company40.210% Peyer James's insider activity →

Parikh Anand Kiran

Insider

15.5M

% of company

60.12%

Change vs last qtr

—

Held since

—

Peyer James

Insider

10.4M

% of company

40.21%

Change vs last qtr

—

Held since

—

7 more holders behind a free account

See every insider and 5%+ holder of Faeth Therapeutics, Inc.

Comments